Tracers / [213Bi]Bi-anti-CD20
[213Bi]Bi-anti-CD20
Also written as [Bi-213]anti-CD20
- Radionuclide
- Bi-213 t½ 45.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- anti-CD20 monoclonal antibody (radioimmunoconjugate)
- Target / mechanism
- CD20 antigen on non-Hodgkin lymphoma cells PMID 23474846
- Clinical application
- Targeted alpha-therapy for radio- and chemoresistant non-Hodgkin lymphoma PMID 23474846
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | — | anti-CD20 antibody (Rituximab, MabThera) Herceptin, Roche, Mississauga, ON | 23474846 2013 Oncotarget Bi-213 for the antibody radiolabelling was derived from an Ac-225/Bi-213 generator system. For the purification of the radioimmunoconjugates PD10 desalting columns (GE Healthcare, Munich, Germany) were used. |
Need this precursor?We can point you to suppliers for [213Bi]Bi-anti-CD20, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 23474846. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 23474846: 'The recombinant humanized anti-CD20-mab Rituximab (MabThera®, Roche, Mannheim, Germany) consists of a human IgG1 kappa constant region'.